SU5416 in Treating Patients With Malignant Mesothelioma

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

August 31, 2000

Primary Completion Date

February 28, 2007

Study Completion Date

February 28, 2009

Conditions
Malignant Mesothelioma
Interventions
DRUG

semaxanib

Trial Locations (10)

46617

Michiana Hematology/Oncology P.C., South Bend

60068

Division of Hematology/Oncology, Park Ridge

60201

Evanston Northwestern Health Care, Evanston

60612

University of Illinois at Chicago, Chicago

60640

Louis A. Weiss Memorial Hospital, Chicago

61602

Oncology/Hematology Associates of Central Illinois, P.C., Peoria

62526

Cancer Care Specialists of Central Illinois, S.C., Decatur

62701

Central Illinois Hematology Oncology Center, Springfield

60637-1470

University of Chicago Cancer Research Center, Chicago

46885-5099

Fort Wayne Medical Oncology and Hematology, Inc., Fort Wayne

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00006014 - SU5416 in Treating Patients With Malignant Mesothelioma | Biotech Hunter | Biotech Hunter